Goldstein Advisors LLC Sells 535 Shares of Natera, Inc. (NASDAQ:NTRA)

Goldstein Advisors LLC trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 15.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,838 shares of the medical research company’s stock after selling 535 shares during the quarter. Goldstein Advisors LLC’s holdings in Natera were worth $307,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. SG Americas Securities LLC boosted its stake in shares of Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after purchasing an additional 60,127 shares during the period. Thematics Asset Management increased its position in shares of Natera by 3.1% during the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after acquiring an additional 2,738 shares during the period. Crestline Management LP increased its position in shares of Natera by 16.0% during the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock worth $4,076,000 after acquiring an additional 8,997 shares during the period. Hamilton Lane Advisors LLC bought a new stake in shares of Natera during the fourth quarter valued at approximately $616,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after purchasing an additional 9,781 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Up 0.2 %

NASDAQ:NTRA traded up $0.21 during mid-day trading on Friday, hitting $122.82. 530,393 shares of the company’s stock traded hands, compared to its average volume of 1,404,220. The company has a fifty day moving average of $109.76 and a 200 day moving average of $98.37. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $124.74. The company has a market capitalization of $15.08 billion, a P/E ratio of -39.05 and a beta of 1.48.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The company’s revenue was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.97) earnings per share. On average, analysts forecast that Natera, Inc. will post -2.43 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, Director Rowan E. Chapman sold 4,856 shares of Natera stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $109.09, for a total transaction of $529,741.04. Following the completion of the sale, the director now directly owns 5,005 shares in the company, valued at approximately $545,995.45. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Rowan E. Chapman sold 4,856 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $109.09, for a total transaction of $529,741.04. Following the sale, the director now directly owns 5,005 shares of the company’s stock, valued at $545,995.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of Natera stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the transaction, the insider now directly owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The disclosure for this sale can be found here. In the last quarter, insiders have sold 100,891 shares of company stock worth $11,136,249. 7.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on NTRA. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research report on Tuesday. Morgan Stanley lifted their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. BTIG Research increased their target price on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Piper Sandler boosted their price target on shares of Natera from $120.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Finally, Stephens reiterated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.07.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.